id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-D-0045-0009,FDA,FDA-2004-D-0045,Waivers From the Requirement To Demonstrate Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form Products and Type A Medicated Articles; Draft Revised Guidance for Industry; Availability,Notice,Notice of Availability,2016-09-16T04:00:00Z,2016,9,2016-09-16T04:00:00Z,,2016-09-16T13:05:43Z,2016-22339,0,0,09000064822183e8
FDA-2004-D-0045-0010,FDA,FDA-2004-D-0045,Draft Guidance for Industry for Waivers From the Requirement to Demonstrate Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form Products and Type A Medicated Articles,Other,Guidance,2016-09-16T04:00:00Z,2016,9,2016-09-16T04:00:00Z,,2024-11-07T23:49:03Z,,1,0,090000648220b184
FDA-2004-D-0045-0008,FDA,FDA-2004-D-0045,Draft Rev GFI Bioequivalence Waivers,Other,,2016-08-03T00:00:00Z,2016,8,,,2016-08-03T18:24:49Z,,0,1,09000064821527bd